Zentalis Pharmaceuticals (ZNTL, $11.06) is predicted by A.I.dvisor to grow by to $11.5 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended up during the month, the odds of an Uptrend continuation are
a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer